Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea · Delayed Price · Currency is KRW 11,400
+220 (1.97%)
At close: Apr 2, 2026
KRX:007570 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 6,905 | 9,032 | -2,409 | 19,385 | 14,032 |
Depreciation & Amortization | 8,344 | 9,824 | 11,971 | 11,767 | 11,227 |
Other Amortization | - | - | - | - | 14.99 |
Loss (Gain) From Sale of Assets | -89.72 | 9.54 | -0.51 | -21.22 | -2.86 |
Asset Writedown & Restructuring Costs | -45 | -2.49 | -40.51 | 25.51 | -263.19 |
Loss (Gain) From Sale of Investments | 8 | -27.43 | -30.57 | 24.78 | - |
Loss (Gain) on Equity Investments | 843.99 | -2,083 | 13,425 | -10,754 | -9,236 |
Provision & Write-off of Bad Debts | 270.6 | -52.33 | -393.8 | -964.92 | 1,067 |
Other Operating Activities | 2,560 | 2,481 | 3,604 | 2,427 | 16,825 |
Change in Accounts Receivable | -325.45 | 1,282 | -1,087 | 3,101 | -10,261 |
Change in Inventory | -7,550 | -7,606 | -5,574 | -16,830 | 5,719 |
Change in Accounts Payable | -1,938 | -3,545 | -3,425 | 6,502 | 4,160 |
Change in Other Net Operating Assets | 3,057 | -3,696 | -1,421 | -8,779 | 18,147 |
Operating Cash Flow | 12,041 | 5,615 | 14,619 | 5,883 | 51,429 |
Operating Cash Flow Growth | 114.44% | -61.59% | 148.49% | -88.56% | -10.53% |
Capital Expenditures | -5,717 | -38,200 | -5,883 | -3,946 | -12,371 |
Sale of Property, Plant & Equipment | 26.97 | - | 0.52 | 20 | 0.92 |
Sale (Purchase) of Intangibles | -4,547 | -2,423 | -949.74 | -12.08 | -2,128 |
Investment in Securities | 3,002 | 3,365 | -4,606 | 28,115 | -565.4 |
Other Investing Activities | 10.3 | 82.53 | -77.65 | -14 | 366.7 |
Investing Cash Flow | -7,225 | -37,175 | -11,516 | 24,163 | -14,671 |
Short-Term Debt Issued | 29,911 | 68,716 | 24,789 | 35,000 | 39,147 |
Long-Term Debt Issued | 15,300 | 8,700 | 6,000 | - | - |
Total Debt Issued | 45,211 | 77,416 | 30,789 | 35,000 | 39,147 |
Short-Term Debt Repaid | -26,200 | -42,000 | -30,000 | -56,500 | -31,147 |
Long-Term Debt Repaid | -542.1 | -717.18 | -2,753 | -3,737 | -10,758 |
Total Debt Repaid | -26,742 | -42,717 | -32,753 | -60,237 | -41,905 |
Net Debt Issued (Repaid) | 18,469 | 34,699 | -1,965 | -25,237 | -2,758 |
Issuance of Common Stock | - | 515.48 | - | - | - |
Repurchase of Common Stock | -1,000 | - | -2,000 | -3,000 | - |
Dividends Paid | -2,881 | -2,974 | -2,992 | -3,942 | -2,350 |
Other Financing Activities | 28.6 | -0.56 | -22 | 183.5 | -31,524 |
Financing Cash Flow | 14,617 | 32,240 | -6,978 | -31,996 | -36,632 |
Foreign Exchange Rate Adjustments | -74.22 | 201.72 | 115.33 | -164.64 | - |
Net Cash Flow | 19,359 | 881.17 | -3,759 | -2,115 | 125.49 |
Free Cash Flow | 6,323 | -32,585 | 8,736 | 1,938 | 39,057 |
Free Cash Flow Growth | - | - | 350.88% | -95.04% | -17.44% |
Free Cash Flow Margin | 2.32% | -12.13% | 3.28% | 0.78% | 16.11% |
Free Cash Flow Per Share | 343.42 | -1767.81 | 484.85 | 106.90 | 2145.40 |
Cash Interest Paid | 4,040 | 3,634 | 3,312 | 2,096 | 1,912 |
Cash Income Tax Paid | 6,775 | 1,598 | 1,239 | 5,108 | 1,320 |
Levered Free Cash Flow | 203.66 | -37,220 | 10,211 | -1,037 | 34,080 |
Unlevered Free Cash Flow | 2,098 | -35,388 | 12,227 | 295.86 | 35,249 |
Change in Working Capital | -6,756 | -13,566 | -11,507 | -16,006 | 17,765 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.